

## Clinical Policy: Interferon Beta-1a (Avonex, Rebif)

Reference Number: CP.CPA.330

Effective Date: 06.01.18

Last Review Date: 05.19

Line of Business: Commercial

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

### Description

Interferon beta-1a (Avonex<sup>®</sup>, Rebif<sup>®</sup>) is an amino acid glycoprotein.

### FDA Approved Indication(s)

Avonex and Rebif are indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

### Policy/Criteria

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that Avonex and Rebif are **medically necessary** when the following criteria are met:

#### I. Initial Approval Criteria

##### A. Multiple Sclerosis (must meet all):

1. Diagnosis of one of the following (a, b, or c):
  - a. Clinically isolated syndrome;
  - b. Relapsing-remitting MS;
  - c. Secondary progressive MS;
2. Prescribed by or in consultation with a neurologist;
3. Age  $\geq$  2 years (for Rebif requests) or  $\geq$  18 years (for Avonex requests);
4. Not prescribed concurrently with other disease modifying therapies for MS (*see Appendix D*);
5. Dose does not exceed one of the following (a or b):
  - a. Avonex: 30 mcg per week (1 vial/syringe/autoinjector per week);
  - b. Rebif: 44 mcg three times per week (1 syringe/autoinjector three times per week).

**Approval duration: 6 months or to the member's renewal date, whichever is longer**

##### B. Other diagnoses/indications

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial.

#### II. Continued Therapy

##### A. Multiple Sclerosis (must meet all):

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy;
3. Not prescribed concurrently with other disease modifying therapies for MS (*see Appendix D*);
4. If request is for a dose increase, new dose does not exceed one of the following (a or b):
  - a. Avonex: 30 mcg per week (1 vial/syringe/autoinjector per week);
  - b. Rebif: 44 mcg three times per week (1 syringe/autoinjector three times per week).

**Approval duration: 6 months or to the member's renewal date, whichever is longer**

**B. Other diagnoses/indications (must meet 1 or 2):**

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.  
**Approval duration: Duration of request or 6 months (whichever is less);** or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – CP.CPA.09 for commercial or evidence of coverage documents;
- B. Primary progressive MS.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

FDA: Food and Drug Administration

MS: multiple sclerosis

*Appendix B: Therapeutic Alternatives*

Not applicable

*Appendix C: Contraindications/Boxed Warnings*

- Contraindication(s): history of hypersensitivity to natural or recombinant interferon beta, albumin or any other component of the formulation
- Boxed warning(s): none reported

*Appendix D: General Information*

- Disease-modifying therapies for MS are: glatiramer acetate (Copaxone<sup>®</sup>, Glatopa<sup>®</sup>), interferon beta-1a (Avonex<sup>®</sup>, Rebif<sup>®</sup>), interferon beta-1b (Betaseron<sup>®</sup>, Extavia<sup>®</sup>), peginterferon beta-1a (Plegridy<sup>®</sup>), dimethyl fumarate (Tecfidera<sup>®</sup>), fingolimod (Gilenya<sup>™</sup>), teriflunomide (Aubagio<sup>®</sup>), alemtuzumab (Lemtrada<sup>®</sup>), mitoxantrone (Novantrone<sup>®</sup>), natalizumab (Tysabri<sup>®</sup>), ocrelizumab (Ocrevus<sup>™</sup>), cladribine (Mavenclad<sup>®</sup>), and siponimod (Mayzent<sup>®</sup>).

**V. Dosage and Administration**

Drug Name	Dosing Regimen	Maximum Dose
Interferon beta-1a (Avonex)	30 mcg IM Q week; may be titrated starting with 7.5 mcg for the first week, increased by 7.5 mcg each week for 3 weeks until target of 30 mcg is reached	30 mcg/week
Interferon beta-1a (Rebif)	Initial dose at 20% of prescribed dose TIW increased over 4 weeks to the targeted dose of either 22 mcg or 44 mcg SC TIW	44 mcg TIW

**VI. Product Availability**

Drug Name	Availability
Interferon beta-1a (Avonex)	Single-use vial: 30 mcg Single-use prefilled autoinjector or syringe: 30 mcg/0.5 mL
Interferon beta-1a (Rebif)	Single-dose autoinjector or prefilled syringe: 8.8 mcg/0.2 mL, 22 mcg/0.5 mL, 44 mcg/0.5 mL

**VII. References**

1. Avonex Prescribing Information. Cambridge, MA: Biogen Inc.; July 2019. Available at <http://www.avonex.com>. Accessed August 2, 2019.
2. Rebif Prescribing Information. Rockland, MA: EMD Serono, Inc; July 2019. Available at <http://www.rebif.com>. Accessed August 2, 2019.
3. Costello K, Halper J, Kalb R, Skutnik L, Rapp R. The use of disease-modifying therapies in multiple sclerosis, principles and current evidence – a consensus paper by the Multiple Sclerosis Coalition. March 2017. Accessed February 4, 2019.
4. Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. *Neurology* 2002; 58(2): 169-178.
5. European Medicines Agency: Avonex: EPAR – Product Information; November 2018. Available at: [https://www.ema.europa.eu/documents/product-information/avonex-epar-product-information\\_en.pdf](https://www.ema.europa.eu/documents/product-information/avonex-epar-product-information_en.pdf). Accessed February 7, 2019.
6. European Medicines Agency: Rebif: EPAR – Product Information; December 2018. Available at: [https://www.ema.europa.eu/documents/product-information/rebif-epar-product-information\\_en.pdf](https://www.ema.europa.eu/documents/product-information/rebif-epar-product-information_en.pdf). Accessed February 7, 2019.
7. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology*. 2018; 90(17): 777-788. Full guideline available at: <https://www.aan.com/Guidelines/home/GetGuidelineContent/904>.

**Coding Implications**

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J1826	Injection, interferon beta-1a, 30 mcg
Q3027	Injection, interferon beta-1a, 1 mcg for intramuscular use
Q3028	Injection, interferon beta-1a, 1 mcg for subcutaneous use

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created: split from CP.CPA.206 Multiple Sclerosis; combined criteria sets for RRMS and SPMS; allowed Avonex for SPMS since it is the same active ingredient as Rebif; added coverage for clinically isolated syndrome per FDA labeling; added age; removed COC statement for reauth; added requirement for no concurrent use with other MS therapies; references reviewed and updated.	01.05.18	05.18
2Q 2019 annual review: no significant changes; references reviewed and updated.	02.07.19	05.19
RT4: updated FDA Approved Indication(s) section to include SPMS per updated FDA labeling; SPMS: removed requirement that member has active relapsing disease per current SPMS management approach; references reviewed and updated.	08.02.19	

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy,

contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.